Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: A meta-analysis of 8 randomized trials

Atherosclerosis

Volumn 222, Issue 2, 2012, Pages 426-433

  De Luca, Giuseppe ^a   Verdoia, Monica ^a   Suryapranata, Harry ^b  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Abciximab; Primary angioplasty; ST elevation myocardial infarction

Indexed keywords

ABCIXIMAB;

ANGIOPLASTY; ARTICLE; BLEEDING; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HEART MUSCLE PERFUSION; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; CORONARY CIRCULATION; CORONARY VESSELS; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; MYOCARDIAL INFARCTION; ODDS RATIO; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861347454     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.02.041     Document Type: Article

References (30)

1. De Luca G., Suryapranata H., Stone G.W., et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005, 293:1759-1765.
2. De Luca G., Navarese E., Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J 2009, 30:2705-2713.
3. European Association for Percutaneous Cardiovascular Interventions, Wijns W., Kolh P., et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010, 31:2501-2555.
4. Hansen P.R., Iversen A., Abdulla J. Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Invasive Cardiol 2010, 22:278-282.
5. Navarese E.P., Kozinski M., Obonska K., et al. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials. Platelets 2011, (Oct). [Epub ahead of print].
6. Thiele H., Wöhrle J., Hambrecht R., et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet 2012, (Feb). [Epub ahead of print].
7. Egger M., Smith G.D. Bias in location and selection of studies. BMJ 1998, 31:61-66.
8. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement Quality of Reporting of Meta-analyses. Lancet 1999, 354:1896-1900. [Review].
9. Bellandi F., Maioli M., Gallopin M., Toso A., Dabizzi R.P. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv 2004, 62:186-192.
10. Thiele H., Schindler K., Friedenberger J., et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008, 118:49-57.
11. Dominguez-Rodriguez A., Abreu-Gonzalez P., Avanzas P., et al. Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention - effects on soluble CD40 ligand concentrations. Atherosclerosis 2009, 206:523-527.
12. Gu Y.L., Kampinga M.A., Wieringa W.G., et al. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial. Circulation 2010, 122:2709-2717.
13. Bertrand O.F., Rodés-Cabau J., Larose E., et al. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study. Am J Cardiol 2010, 105:1520-1527.
14. Iversen A.Z., Galatius S., Abildgaard U., et al. Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year. Cardiology 2011, 120:43-49.
15. Dave RM. Improving outcome of STEMI PCI: preliminary results of crystal AMI trial. Available from: <> [assessed 28.05.11]. http://www.clinicaltrialresults.org/Slides/CRYSTAL_Slides.ppt.
16. De Luca G., van't Hof A.W., Ottervanger J.P., et al. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Eur Heart J 2005, 26:662-666.
17. De Luca G., van't Hof A.W., Ottervanger J.P., et al. Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am Heart J 2005, 150:557-562.
18. De Luca G., Gibson C.M., Bellandi F., et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis 2009, 207:181-185.
19. De Luca G., van't Hof A.W., de Boer M.J., et al. Impaired myocardial perfusion is a major explanation of the poor outcome observed in patients undergoing primary angioplasty for ST-segment-elevation myocardial infarction and signs of heart failure. Circulation 2004, 109:958-961.
20. De Luca G., Bellandi F., Huber K., et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J Thromb Haemost 2011, 9:2361-2370.
21. Marciniak S.J., Mascelli M.A., Furman M.I., et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost 2002, 87:1020-1025.
22. Collet J.P., Montalescot G., Lesty C., et al. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol 2001, 21:142-148.
23. Hantgan R.R., Moussa S.A. Inhibition of platelet-mediated clot retraction by integrin antagonists. Thromb Res 1998, 89:271-279.
24. Cohen I., Berk D.L., White J.G. The effect of peptides and monoclonal antibodies that bind to platelet glycoprotein IIb/IIIa complex on the development of clot tension. Blood 1989, 73:1880-1887.
25. Tam S.H., Sassoli P.M., Jordan R.E., Nakada M.T. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/III and avb3 integrins. Circulation 1998, 98:1085-1091.
26. Reverter J.C., Béguin S., Kessels H., Kumar R., Hemker H.C., Coller B.S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and clinical restenosis. J Clin Invest 1996, 98:863-874.
27. Neumann F.J., Zohlnhöfer D., Fakhoury L., Ott I., Gawaz M., Schömig A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999, 34:1420-1426.
28. De Luca G., Dudek D., Sardella G., Marino P., Chevalier B., Zijlstra F. Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. Eur Heart J 2008, 29:3002-3010.
29. De Luca G., Suryapranata H., Chiariello M. Prevention of distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction. A review of current status. Thromb Haemost 2006, 96:700-710.
30. Gibson C.M., Maehara A., Lansky A.J., et al. Rationale and design of the INFUSE-AMI study: a 2×2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. Am Heart J 2011, 161(478-486):e7.